Naveen Pemmaraju, MD

Shifting his focus to treatment strategies in myelofibrosis, Naveen Pemmaraju, MD, reviews the current drug armamentarium and explains how it ties into disease modification.

Expert hematologist-oncologist Naveen Pemmaraju, MD, highlights current strategies in diagnosing and stratifying patients with myelofibrosis.

Closing out their discussion on myeloproliferative neoplasms, key opinion leaders share excitement for future evolutions in the treatment paradigm.

Following their overview on novel treatment modalities in myeloproliferative neoplasms, expert panelists consider how best to sequence and manage novel therapies in practice.

A broad and comprehensive review of novel targeted agents under investigation in the setting of myeloproliferative neoplasm management.

Key opinion leaders on myeloproliferative neoplasms review the potential of CALR as a therapeutic target following data from the ASH 2022 Annual Meeting.

Expert panelists consider the ongoing role of transplant for patients with myelofibrosis and discuss when it is more appropriate to explore systemic therapy options.

Closing out their discussion on the management of myelofibrosis, panelists highlight updated data with fedratinib and ruxolitinib, respectively.

A brief review of the biology of myelofibrosis, the potential for disease modification, and subsequent implications for treatment.

Key opinion leaders on myeloproliferative neoplasms review clinical data behind pacritinib therapy in the setting of myelofibrosis.

Switching their focus to myelofibrosis management, expert panelists reflect on clinical data behind momelotinib, a novel JAK2 inhibitor.

Shared insight on how a patient’s symptom burden can impact management strategies within essential thrombocytopenia and polycythemia vera.

Expert perspectives on the respective treatment landscapes of essential thrombocytopenia (ET) and polycythemia vera (PV) following the ASH 2022 Annual Meeting.

Naveen Pemmaraju, MD, discusses the characteristics of disease progression in patients with myelofibrosis.

Naveen Pemmaraju, MD, discusses current treatment strategies in blastic plasmacytoid dendritic cell neoplasm.

Naveen Pemmaraju, MD, discusses the potential role of novel therapies in myeloproliferative neoplasms.

Naveen Pemmaraju, MD, discusses the need to develop novel therapies in myeloproliferative neoplasms.

Naveen Pemmaraju, MD, discusses the challenges of targeting TP53-mutant myelodysplastic syndrome and acute myeloid leukemia.

Naveen Pemmaraju, MD, discusses the need for collaboration when diagnosing and treating patients with myelofibrosis.

Naveen Pemmaraju, MD, discusses methods to address anemia in patients with myelodysplastic syndromes.

Naveen Pemmaraju, MD, associate professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the ongoing phase I/II trial of tagraxofusp (SL-401; Elzonris) in patients with intermediate- or high-risk relapsed/refractory myelofibrosis.

Naveen Pemmaraju, MD, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the trial of SL-401 in blastic plasmacytoid dendritic cell neoplasms.

Naveen Pemmaraju, MD, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the use of SL-401 in patients with blastic plasmacytoid dendritic cell neoplasms.

Naveen Pemmaraju, MD, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the clinical trial results for LCL161 in patients with intermediate or high-risk myelofibrosis.